MIAMI, FLORIDA (Sept. 23, 2025) – Sylvester Comprehensive Cancer Center , part of University of Miami Miller School of Medicine, will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening and reducing unnecessary callbacks and anxiety for patients.
The study, known as the PRISM Trial (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography), is supported by a $16 million award from the Patient-Centered Outcomes Research Institute (PCORI). The study will involve hundreds of thousands of mammograms interpreted at academic medical centers and breast imaging facilities in California, Florida, Massachusetts, Washington and Wisconsin. The AI support tool studied will be Transpara by ScreenPoint Medical with clinical workflow integration provided by the Aidoc aiOS platform.
“As the first major randomized trial of AI in breast cancer screening in the U.S., this study represents a pivotal step,” said Jose Net, M.D. , director of breast imaging services at Sylvester, associate professor of clinical radiology at the Miller School and co-principal investigator of the study. “Our goal is to rigorously and objectively assess AI’s impact — identifying who benefits and who may not. Radiologists remain firmly in control of all diagnostic decisions.”
A Pressing Question in Breast Cancer Care
Breast cancer remains one of the leading causes of cancer death among women in the U.S. While routine mammography screening reduces mortality through early detection, it also has drawbacks — including false positives that can lead to unnecessary testing, anxiety and costs, and missed cancers.
“While AI offers substantial promise, it also prompts critical questions,” said Net. “Our focus is on understanding whether AI genuinely enhances cancer detection by radiologists or simply leads to more false alarms.”
Patient-centered by Design
What makes PRISM different is its emphasis on patient-centered research. The trial was developed in close partnership with patient advocates, clinicians, health system leaders and policymakers.
Each participating facility will continue routine screening as usual, with no changes to the patient experience. Mammograms will be randomly assigned to be interpreted either by a radiologist on their own or with assistance from an FDA-cleared AI support tool. In all cases, a radiologist reads the exam and makes the final decision.
“A trial of this magnitude focusing on AI in breast cancer screening has never been conducted in the U.S.,” stated Net. “The findings will influence not only clinical practices but also insurance policies, technology integration, and patient interactions. According to Net, while there is significant optimism that AI will enhance health care, few rigorous studies have assessed its actual impact in real-world settings.
“This trial presents an opportunity to produce reliable evidence with a strong emphasis on the patient's perspective,” he stated.
In addition to analyzing cancer detection and recall rates, the study will include focus groups and surveys to capture how patients and radiologists perceive and trust AI-assisted care.
Collaborative Effort Across Six States
The PRISM trial brings together seven leading academic medical centers:
Striking the Right Balance
Net emphasized that the goal is not to replace human expertise but to understand how AI might complement it. “Our skilled radiologists will always have the final say. While AI can serve as a helpful assistant, it is ultimately the radiologist who is in control.”
The trial is expected to inform future policy decisions, best practices in screening, and how to most effectively integrate emerging technologies into patient care.
Read more about Sylvester research on the InventUM blog and follow @SylvesterCancer on X for the latest news on its research and care.
# # #